McKesson Research and Development Expenses 2010-2024 | MCK

McKesson annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • McKesson research and development expenses for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • McKesson research and development expenses for the twelve months ending September 30, 2024 were $0M, a NAN% increase year-over-year.
  • McKesson annual research and development expenses for 2024 were $0B, a NAN% decline from 2023.
  • McKesson annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • McKesson annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
McKesson Annual Research and Development Expenses
(Millions of US $)
2024 $
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $125
2017 $341
2016 $392
2015 $392
2014 $457
2013 $433
2012 $402
2011 $407
2010 $376
2009 $364
McKesson Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $78.151B $308.951B
McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
Stock Name Country Market Cap PE Ratio
Becton Dickinson (BDX) United States $64.352B 16.92
Cardinal Health (CAH) United States $28.637B 15.53
West Pharmaceutical Services (WST) United States $22.024B 44.99
Labcorp (LH) United States $19.758B 16.38
Cooper (COO) United States $19.726B 28.08
Align Technology (ALGN) United States $16.616B 31.80
Henry Schein (HSIC) United States $9.331B 17.78
Merit Medical Systems (MMSI) United States $6.102B 31.16
DENTSPLY SIRONA (XRAY) United States $3.753B 10.20
CONMED (CNMD) United States $2.216B 18.49
Patterson (PDCO) United States $1.799B 9.49
STAAR Surgical (STAA) United States $1.288B 47.53
Lifevantage (LFVN) United States $0.170B 22.60
Pro-Dex (PDEX) United States $0.147B 29.36